Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets

  • Iqbal S. Grewal
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)


Since the discovery of tumor necrosis factor TNFα about 25 years ago, TNF superfamily has grown to a large family of related proteins consisting of over 20 members that signal through over 30 receptors. Members of this superfamily have wide tissue distribution and play important roles ranging from regulation of the normal biological processes such as immune responses, hematopoiesis and morphogenesis to their role in tumorigenesis, transplant rejection, septic shock, viral replication, bone resorption and autoimmunity. Thus, many approaches to harness the potency of TNF superfamily members to treat human diseases have been developed. Indeed, TNF and TNF agonistic molecules have been approved for human use in the United States and other countries. Many other TNF family members show promise for several therapeutic applications, including cancer, infectious disease, transplantation and autoimmunity. This chapter will give overview of TNF superfamily for exploitation for therapeutic use in humans.


Isolate Limb Perfusion Profound Role Autoimmune Lymphoproliferative Syndrome CD40L Gene Tumor Necrosis Factor Ligand Superfamily 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bruns P. Die heilwirkung des erysipels auf geschwulste. Beitr Klin Chir 1868; 3:443–446.Google Scholar
  2. 2.
    Coley WB. Contribution to the knowledge of sarcoma. Ann Surg 1891; 14:199–220.PubMedCrossRefGoogle Scholar
  3. 3.
    Shear MJ, Turner FC. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from serratia marcescens (bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 1943; 4:81–97.Google Scholar
  4. 4.
    O’Malley WE, Achinstein B, Shear MJ. Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide and induced tolerance. J Natl Cancer Inst 1962; 29:1169–1175.Google Scholar
  5. 5.
    Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666–3670.PubMedCrossRefGoogle Scholar
  6. 6.
    Aggarwal BB, Kohr WJ, Hass PE et al. Human tumor necrosis factor. Production, purification and characterization. J Biol Chem 1985; 260:2345–2354.PubMedGoogle Scholar
  7. 7.
    Pennica D, Nedwin GE, Hayflick JS et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724–729.PubMedCrossRefGoogle Scholar
  8. 8.
    Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85:3378–3404.PubMedGoogle Scholar
  9. 9.
    Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745–756.PubMedCrossRefGoogle Scholar
  10. 10.
    Dampsey PW, Doyle SE, He JQ et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14:193–209.CrossRefGoogle Scholar
  11. 11.
    Kischkel FC, Lawrence DA, Chuntharapai A et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12:611–620.PubMedCrossRefGoogle Scholar
  12. 12.
    Darnay BG, Ni J, Moore PA et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 1999; 274:7724–7731.PubMedCrossRefGoogle Scholar
  13. 13.
    Gibson SB, Oyer R, Spalding AC et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20:205–212.PubMedCrossRefGoogle Scholar
  14. 14.
    McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133–144.PubMedCrossRefGoogle Scholar
  15. 15.
    Straus SE, Jaffe ES, Puck JM et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98:194–200.PubMedCrossRefGoogle Scholar
  16. 16.
    Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 1998; 43:2–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Ramesh N, Seki M, Notarangelo LD et al. The hyper-IgM (HIM) syndrome. Springer Semin Immunopathol 1998; 19:383–399.PubMedCrossRefGoogle Scholar
  18. 18.
    Hughes AE, Ralston SH, Marken J et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24:45–48.PubMedCrossRefGoogle Scholar
  19. 19.
    Botchkarev VA, Fessing MY. EDAR signaling in the control of hair follicle development. J Investig Dermatol Symp Proc 2005; 10:247–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Takayama H, Takakuwa T, Tsujimoto Y et al. Frequent Fas gene mutations in testiccular germ cell tumors. Am J Pathol 2002; 161:635–641.PubMedGoogle Scholar
  21. 21.
    Takayama H, Takakuwa T, Dong Z et al. Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens. Lab Invest 2001; 81:283–288.PubMedGoogle Scholar
  22. 22.
    Yan M, Brady JR, Chan B et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B-cell deficiency. Curr Biol 2001; 11:1547–1552.PubMedCrossRefGoogle Scholar
  23. 23.
    Feinberg B, Kurzrock R, Talpaz M et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6:1328–1334.PubMedGoogle Scholar
  24. 24.
    Wielockx B, Lannoy K, Shapiro SD et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001; 7:1202–1208.PubMedCrossRefGoogle Scholar
  25. 25.
    Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4:429–437.PubMedCrossRefGoogle Scholar
  26. 26.
    Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420–430.PubMedCrossRefGoogle Scholar
  27. 27.
    Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4:333–339.PubMedCrossRefGoogle Scholar
  28. 28.
    Chuntharapai A, Dodge K, Grimmer K et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166:4891–4898.PubMedGoogle Scholar
  29. 29.
    Ichikawa K, Liu W, Zhao L et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954–960.PubMedCrossRefGoogle Scholar
  30. 30.
    Buchsbaum DJ, LoBuglio AF. Targeting of 125I-labeled B-lymphocyte stimulator. J Nucl Med 2003; 44:434–436.PubMedGoogle Scholar
  31. 31.
    Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges. In: Grewal IS, ed. Therapeutic Targets of the TNF Superfamily. Austin: Landes Bioscience, 2008; 8–36.Google Scholar
  32. 32.
    Seshasayee D, Lee WP, Zhou M et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest 2007; 117:3868–78.PubMedCrossRefGoogle Scholar
  33. 33.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  34. 34.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76:959–62.PubMedCrossRefGoogle Scholar
  35. 35.
    Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33:29–55.PubMedCrossRefGoogle Scholar
  36. 36.
    Griffith TS, Brunner T, Fletcher SM et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270:1189–92.PubMedCrossRefGoogle Scholar
  37. 37.
    Song K, Chen Y, Göke R et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191:1095–104.PubMedCrossRefGoogle Scholar
  38. 38.
    Watts TH. TNF/TNFR family members in costimulation of T-cell responses. Annu Rev Immunol 2005; 23:23–68.PubMedCrossRefGoogle Scholar
  39. 39.
    Mackay F, Silveira PA, Brink R. B-cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007; 19:327–36.PubMedCrossRefGoogle Scholar
  40. 40.
    Adams AB, Larsen CP, Pearson TC et al. The role of TNF receptor and TNF superfamily molecules in organ transplantation. Am J Transplant 2002; 2:12–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol 2008; 181:101–29.PubMedCrossRefGoogle Scholar
  42. 42.
    Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13:391–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148–55.PubMedCrossRefGoogle Scholar
  44. 44.
    Lans TE, Bartlett DL, Libutti SK. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 2001; 7:784–90.PubMedGoogle Scholar
  45. 45.
    Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: Comparison among infliximab, etanercept and adalimumab. Arthritis Rheum 2008; 58:1248–1257.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Iqbal S. Grewal
    • 1
  1. 1.Department of Preclinical TherapeuticsSeattle Genetics, Inc.BothellUSA

Personalised recommendations